India · Delayed Price · Currency is INR Dhanuka Agritech Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY 2026 saw a year-over-year decline in revenue and profit due to weak agrochemical demand, regulatory challenges, and adverse weather. Despite this, new product launches, Dahej plant ramp-up, and strong cash reserves position the company for recovery and long-term growth.
-
Q2 FY 2026 saw revenue and profit decline YoY due to erratic rainfall and regulatory hurdles in biostimulants, with herbicide sales most affected. Guidance for FY 2026 is flattish revenue, stable gross margins, and a 100 bps EBITDA margin decline, while new product launches and digital initiatives continue.
-
Revenue grew 7% year-over-year in Q1 FY26, with EBITDA and PAT also rising. Despite subdued herbicide demand and high channel inventory, management maintains double-digit growth guidance for FY26, with a slight EBITDA margin decline expected. Dividend and buyback completed.
Fiscal Year 2025
-
Achieved record FY 2025 revenue and profit growth, driven by new product launches and global expansion. Outlook for FY 2026 is higher double-digit revenue growth, stable EBITDA margin, and continued investment in innovation and international markets.
-
Q3 FY25 saw double-digit revenue and profit growth, driven by new product launches and strong domestic performance. The company acquired global rights to two Bayer molecules, targeting international expansion, and expects continued volume-led growth with stable margins.
-
Q2 FY25 saw 6% revenue and 13% EBITDA growth, driven by strong new product launches and improved margins. Full-year revenue guidance was revised to 16%, with EBITDA margin now expected to improve by 100 basis points over last year.
-
Q1 FY25 saw revenue rise 33.74% and EBITDA up 64.46% year-over-year, driven by strong herbicide sales and new product launches. FY25 revenue growth guidance is raised to 18%-20%, with margins expected to normalize. Leadership transition and a share buyback were key developments.
Fiscal Year 2024
-
Acquisition of international rights for two fungicide products enables expansion into 20+ countries, with manufacturing to shift to India and expected 10%-15% CAGR over five years. The INR 165 crore deal leverages established brands and markets, aiming for stable margins and gradual revenue ramp-up.